Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

MRI-Guided Ultrasound Energy in Treating Patients With Stage I, Stage II, or Stage IIIA Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00008437
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : July 2, 2012
Information provided by (Responsible Party):

Brief Summary:

RATIONALE: Imaging procedures, such as MRI, may allow the doctor to better detect the tumor. Highly focused ultrasound energy may be able to kill tumor cells by heating the breast tumor cells without affecting the surrounding tissue.

PURPOSE: Phase II trial to study the effectiveness of MRI-guided ultrasound energy in treating women who have stage I, stage II, or stage IIIA breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Device: high-intensity focused ultrasound ablation Phase 2

Detailed Description:


  • Determine the incidence and severity of adverse events during and after MRI-guided focused ultrasound ablation in women with stage I-IIIA breast cancer.
  • Determine the ability to accurately and thoroughly coagulate a target volume of breast carcinoma, in terms of real-time target volume temperature profile, follow-up MRI, and histology, using this procedure.
  • Compare the appearance of gross and microscopic histopathologic tissue post coagulation with the pre- and post-coagulation magnetic resonance appearance of the targeted volume and measure any residual cancer cells in patients after this procedure.
  • Determine patient acceptance of this procedure, in terms of positioning, pain, safety, and follow-up cosmesis.

OUTLINE: This is a pilot study.

Patients undergo MRI-guided focused ultrasound (MRgFUS) ablation of the breast lesion using a series of pulses. Within 72 hours after MRgFUS procedure, patients undergo gadolinium-enhanced MRI to evaluate ablation borders. Within 7-10 days after MRgFUS procedure, patients undergo an ultrasound exam. Guide wires may be placed to assist in pre-surgical lesion localization. Within 10-21 days after MRgFUS procedure, patients undergo segmental resection or mastectomy.

Patients are followed at 5-10 days post-surgery.

PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Pilot Study of MR-Guided Focused Ultrasound for Tissue Coagulation in Women With Breast Cancer: MR Imaging and Histopathic Correlation, An Assessment or Target Accuracy and Patient Acceptance
Study Start Date : December 2000
Actual Primary Completion Date : December 2000
Actual Study Completion Date : December 2000

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed invasive breast cancer (T1, N0-2, M0)
  • Single focal lesion no greater than 3.5 cm in diameter by MRI
  • No lesions difficult to target, defined as less than 1 cm from skin, nipple, or rib cage
  • No microcalcifications as sole sign of disease
  • No extensive intraductal components on core biopsy, defined as intraductal carcinoma comprising 25% or more of the invasive breast cancer AND intraductal carcinoma in surrounding normal tissue
  • No breast implants
  • Hormone receptor status:

    • Not specified



  • 18 and over


  • Female

Menopausal status:

  • Not specified

Performance status:

  • Karnofsky 80-100%

Life expectancy:

  • At least 5 years


  • No hemolytic anemia (hematocrit less than 30%)


  • Not specified


  • Not specified


  • No heart disease
  • No unstable angina pectoris requiring medication
  • No myocardial infarction within the past 6 months
  • No congestive heart failure requiring medication
  • No diastolic blood pressure greater than 100 mm Hg while receiving medication to treat hypertension
  • No cerebrovascular accident (CVA) within the past 6 months
  • No multiple CVAs
  • No cardiac pacemakers


  • No chronic obstructive pulmonary disease
  • No other lung disease
  • No sleep apnea or airway problems
  • No severe asthma


  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No contraindications to MRI (e.g., implanted medical devices)
  • Must be able to lie prone and still for up to 150 minutes
  • Weight no greater than 250 pounds
  • No severe arthritis
  • No severe claustrophobia
  • No grand mal seizures
  • No insulin-dependent diabetes mellitus
  • No prior reaction to gadolinium-based contrast agent
  • Able to communicate sensations during procedure


Biologic therapy:

  • Not specified


  • At least 3 months since prior chemotherapy

Endocrine therapy:

  • Concurrent hormone replacement therapy allowed
  • Concurrent tamoxifen allowed
  • No concurrent steroids


  • No prior external radiotherapy or laser therapy to ipsilateral breast


  • See Disease Characteristics


  • No concurrent anti-arrhythmic drugs
  • No concurrent immunosuppressive medication
  • No concurrent anticoagulation therapy
  • No concurrent dialysis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00008437

Layout table for location information
United States, Minnesota
Mayo Clinic Cancer Center
Rochester, Minnesota, United States, 55905
Canada, Quebec
CHUM Hopital Saint-Luc
Montreal, Quebec, Canada, H2X 3J4
Sponsors and Collaborators
Layout table for investigator information
Study Chair: Robert W. Newman InSightec
Layout table for additonal information
Responsible Party: InSightec Identifier: NCT00008437    
Other Study ID Numbers: CDR0000068417
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: July 2, 2012
Last Verified: June 2012
Keywords provided by InSightec:
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases